

# **AAP 2018 RED BOOK TUBERCULOSIS: IGRAS AND THE TREATMENT OF TB INFECTION**

WD4094

**PROGRAM DESCRIPTION:** The goal of this activity is to recognize that the AAP now will consider three different regimens for the treatment of tuberculosis infection to be acceptable for children and adolescents; identify why the AAP will now recommend the routine use of IGRAs in children down to 2 years of age and discuss the use of IGRAs by many experts in children younger than two.

## **OBJECTIVES:**

At the conclusion of the session, the participant will be able to:

1. List three different regimens for the treatment of tuberculosis infection to be acceptable for children and adolescents as recognized by the AAP.
2. Describe the routine use of interferon-gamma release assays [IGRAs] in children down to 2 years of age now recommended by the AAP.
3. Describe the use of interferon-gamma release assays [IGRAs] by many experts in children younger than two.

## **FACULTY/ CREDENTIALS:**

**Jeffrey Starke, MD  
Baylor College of Medicine; Texas  
Children's Hospital**

## **ORIGINATION DATE**

August 1, 2018

## **RENEWAL DATE:**

## **EXPIRATION DATE:**

August 1, 2020

## **URL:**

to be determined

## **HARDWARE/SOFTWARE:**

Computer Hardware; Internet connection;  
web browser

## **MATERIALS:**

None

**TARGET AUDIENCE:** Physicians, Registered Nurses, Advanced Practice Nurses, Licensed Practical/Vocational Nurses, Medical Assistants, Physician Assistants, and other Health Educators

**PREREQUISITES:** None

**FORMAT:** Web on demand

**CONTACT INFORMATION:** Office of Jessica Quintero, M.Ed, (210) 531-4568

**ACCREDITATION STATEMENTS:**

**CME:** This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the **Centers for Disease Control and Prevention** and **Heartland National TB Center**. The Centers for Disease Control and Prevention is accredited by the (ACCME®) to provide medical education for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Centers for Disease Control and Prevention designates this **enduring material** for a maximum of **1.25 AMA PRA Category 1 Credits™**.

**CNE:** The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides **1.2** contact hours.

**CEU:** The Centers for Disease Control and Prevention is authorized by IACET to offer **0.1** CEU's for this program.

**DISCLOSURE:** In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial

products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, our presenters, content experts, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of Dr. Jeffrey R. Starke who wishes to disclose that he is a member of the Data Safety Monitoring Board for Otsuka Pharmaceuticals for the pediatric studies of delamanid, a new drug for MDR-TB. ). New TB drug not to be discussed in the talk. Planning committee reviewed content to ensure there is no bias.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

The Centers for Disease Control and Prevention and **Heartland National TB Center** are jointly providing the CNE for this activity.

CDC did not accept commercial support for this continuing education activity.

## **Instructions for Obtaining Continuing Education (CE)**

In order to receive continuing education (CE) for ***WD4094 AAP 2018 Red Book Tuberculosis: IGRAs and the Treatment of TB Infection*** please visit [TCEO](#) and follow these [9 Simple Steps](#) before **August 1, 2020**.

Complete the activity

Complete the Evaluation at [www.cdc.gov/GetCE](http://www.cdc.gov/GetCE)

Pass the posttest at 75% at [www.cdc.gov/GetCE](http://www.cdc.gov/GetCE)

**FEES:** No fees are charged for CDC's CE activities.